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Abstract
Background: Previous studies have demonstrated an association between polymorphisms in the regulatory regions of
Cyclophilin A (CypA) and susceptibility to both HIV-1 infection and disease progression. Here we studied whether these
polymorphisms are associated with susceptibility to HIV-1 infection and disease progression in the Amsterdam Cohort on
HIV-1 infection and AIDS (ACS) in a group of men having sex with men (MSM) and drug users (DU).
Methodology/Principal Findings: We screened participants of the ACS for the C1604G and A1650G polymorphisms in the
regulatory regions of CypA. The prevalence of the 1650G allele was significantly higher in high risk seronegative MSM than
in HIV-1 infected MSM. However, C1604G or A1650G were not associated with the clinical course of infection in MSM of the
ACS. Interestingly, participants of the ACS-DU who carried the 1604G allele showed a significantly accelerated progression
when viral RNA load above 10
4.5 copies per ml plasma was used as an endpoint in survival analysis.
Conclusion/Significance: The results obtained in this study suggest that the A1650G polymorphism in the regulatory
region of the CypA gene may be associated with protection from HIV-1 infection, while the 1604G allele may have a weak
association with the clinical course of infection in DU.
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Introduction
The peptidyl prolyl isomerase Cyclophilin A (CypA) is a
cytoplasmic factor that is essential for efficient infection of HIV-1
[1–3]. It is specifically incorporated into the HIV-1 virion which is
mediated through an interaction with the capsid protein of which
an exposed loop between helices 4 and 5 mimic a natural ligand
for CypA [4,5]. Although CypA is incorporated in the virion, the
presence of CypA in the target cell has the more significant effect
on virus replication [6–9]. The molecular mechanism by which
CypA enhances infection is largely unknown. CypA can catalyze
the cis/trans isomerization of prolyl-peptide bonds in the
HIV-1 capsid protein [10], which suggests that CypA has a
possible role in uncoating of the viral core following entry into the
cytoplasm.
Recently, CypA has gained a lot of interest when it was
identified as a cofactor for the tri-partite containing motif (Trim)5a
in several simian species [11–14]. Trim5a is a retroviral restriction
factor that associates with the capsid protein and blocks HIV-1
infection at an early step following entry of the viral core into the
cytoplasm [15]. Moreover, Trim5-CypA fusion proteins have been
discovered in several simian species [16,17], suggesting that CypA
in some instances can function as a capsid recognition domain for
antiretroviral proteins.
Polymorphisms in human genes that serve as HIV-1 cofactors
or restriction factors have been described to influence susceptibility
to HIV-1 and disease progression. For example, polymorphisms in
chemokine receptors that serve as HIV-1 coreceptors and their
natural ligands have been associated with susceptibility to infection
as well as disease progression [18–21]. Recently, polymorphisms in
cellular factors like Apobec3G, CUL5 and Trim5a, that are
directly or indirectly involved in innate immunity have also been
demonstrated to have an effect on the clinical course of infection
[22–24].
Previously 11 polymorphisms in the CypA gene have been
identified none of which were located in the coding region of the
gene [25]. Two of these SNPs (A1604G and C1650G) might affect
CypA expression levels based on their location in the promoter
region of the CypA gene and these polymorphism have been
demonstrated to affect susceptibility to HIV-1 infection and
disease progression [25,26]. Here we studied the role of SNPs in
the regulatory region of CypA gene on HIV-1 susceptibility and
course of HIV-1 infection in participants of the Amsterdam
Cohort Studies on HIV-1 infection and AIDS (ACS).
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Distribution of the regulatory polymorphisms C1604G
and A1650G in the CypA gene and the effect on
susceptibility to HIV-1 infection
The haplotype frequency of polymorphisms C1604G and
A1650G in the regulatory region of the CypA gene was studied
in three groups: HIV-1 positive MSM of the ACS (n=334), MSM
of the ACS who remained seronegative despite reported high-risk
behavior (High-risk seronegatives, HRSN; n=68), and HIV-1
negative blood donors (controls) (n=104). For all groups, genotype
distributions and minor allele frequencies are shown in Table 1.
Although a higher allele frequency of C1604G was observed in the
HIV-1 infected MSM as compared to the HRSN participants and
controls, this difference was not statistically significant indicating
that the C1604G is not associated with susceptibility to HIV-1
infection (Table 1).
The minor allele frequency of the A1650G polymorphism in the
HRSN was significantly increased as compared to HIV-1 positive
MSM, suggesting that the 1650G allele may be associated with a
decreased susceptibility to HIV-1 infection in participants of the
ACS.
Effects of regulatory CypA polymorphisms on disease
progression
Next, we examined the influence of polymorphisms C1604G
and A1650G on the clinical course of infection in HIV-1 positive
MSM of the ACS. Kaplan Meier and Cox proportional hazard
analyses were used to test for potential differences in rates of
progression to CD4+ T cells below 200 cells per ml, clinical AIDS
according to the CDC definition of 1987 and 1993 [27,28] or
plasma viral RNA load above 10
4.5 copies per ml between
individuals who carried the major or minor allele (dominant
model). The C1604G and the A1650G polymorphisms were not
associated with survival time among MSM of the ACS,
independent of the endpoints used for analysis (Table 2). In
addition, both polymorphisms were also not associated with CD4+
T cell number or plasma viral RNA load at setpoint in HIV-1
positive MSM (data not shown).
Similar analyses were performed in the ACS of drug users (DU,
n=120). In this cohort, 9% of the individuals were heterozygous
for C1604G (minor allele frequency of 0.046) and 25.4% were
heterozygous for A1650G (minor allele frequency of 0.129). None
of the individuals was homozygous for either 1604G or 1650G.
The minor allele frequency for the C1604G and A1650G
polymorphism among DU was similar to the frequencies observed
in the controls (Table 1).
Also in participants of the ACS-DU, the minor alleles of
C1604G and A1650G were not associated with progression to a
first CD4+ T cell count below 200 cells per ml blood, or clinical
AIDS (table 3). However, carriers of the minor allele of C1604G
showed a significantly accelerated progression towards a viral
RNA load above 10
4.5 copies per ml plasma (log rank p=0.007,
RH 2.55, CI95% 1.252–5.171; p=0.01) (Figure 1, table 3). DU
carrying the A1650G minor allele tended to have a somewhat
slower progression towards viral RNA load above 10
4.5 copies per
ml plasma, albeit not statistically significant (Figure 1, table 3). No
Table 1. Genotype distributions of the CypA SNPs C1604G and A1650G and risk for HIV-1 infection.
SNP Risk group Number Genotype frequency (%) Controls or HRSN vs. HIV-1+MAJ vs. HZ+MIN
MAJ HZ MIN OR (95% CI) p-value
C1604G HIV-1+ 334 279 (83.3) 52 (15.5) 4 (1.2)
HRSN 68 60 (88.2) 8 (11.8) 0 (0.0) 0.66 (0.30–1.46) 0.31
Controls 104 92 (88.5) 11 (10.6) 1 (1.0) 0.65 (0.33–1.26) 0.20
A1650G HIV-1+ 334 249 (74.6) 75 (22.5) 10 (3.0)
HRSN 68 42 (61.8) 21 (30.9) 5 (7.4) 1.82 (1.05–3.14) 0.03
Controls 104 74 (71.2) 23 (22.1) 7 (6.7) 1.19 (0.73–1.94) 0.48
MAJ=major genotype; HZ=heterozygous genotype; MIN=minor genotype.
doi:10.1371/journal.pone.0003975.t001
Table 2. Effects of CypA SNPs C1604G and A1650G on
disease progression in the Amsterdam cohort of MSM.
SNP Endpoint Number Events RH (95% C.I.) p-value
C1604G AIDS (CDC1987) 334 211 0.91 (0.63–1.31) 0.61
AIDS (CDC1993) 333 235 0.84 (0.59–1.20) 0.34
CD4,200 cells/ml 333 199 0.84 (0.57–1.23) 0.37
RNA.10
4.5 copies/ml 331 232 1.02 (0.71–1.45) 0.92
A1650G AIDS (CDC 1987) 334 211 0.97 (0.71–1.33) 0.87
AIDS (CDC1993) 333 235 1.07 (0.80–1.43) 0.67
CD4,200 cells/ml 333 199 0.98 (0.70–1.36) 0.89
RNA.10
4.5 copies/ml 331 232 0.88 (0.65–1.20) 0.42
P-values were from Cox proportional hazard analysis.
doi:10.1371/journal.pone.0003975.t002
Table 3. Effects of CypA SNPs C1604G and A1650G on
disease progression in DU of the Amsterdam cohort.
SNP Endpoint Number Events RH (95%CI ) p-value
C1604G AIDS (CDC 1987) 120 41 1.32 (0.52–3.39) 0.56
AIDS (CDC1993) 120 72 1.27 (0.61–2.65) 0.53
CD4,200 cells/ml 120 54 1.42 (0.64–3.15) 0.39
RNA.10
4.5 copies/ml 120 46 2.55 (1.25–5.17) 0.01
A1650G AIDS (CDC 1987) 120 41 1.31 (0.69–2.51) 0.41
AIDS (CDC1993) 120 72 1.24 (0.75–2.06) 0.39
CD4,200 cells/ml 120 54 1.27 (0.71–2.26 0.42
RNA.10
4.5 copies/ml 120 46 0.57 (0.27–1.18) 0.13
P-values were from Cox proportional hazard analysis.
doi:10.1371/journal.pone.0003975.t003
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the C1604G or A1650G polymorphism was observed (data not
shown).
Effect of regulatory polymorphisms in CypA on CypA
expression levels and HIV-1 replication
Next we analyzed whether the C1604G and A1650G
polymorphisms in the regulatory regions of the CypA gene were
associated with altered CypA expression levels. To this end, we
performed quantitative RT-PCR on CypA mRNA levels in
peripheral blood mononuclear cells (PBMC) of 28 healthy blood
donors genotyped for the C1604G and A1650G polymorphism.
We observed a reduced CypA expression in PBMC that were
heterozygous for the 1604G minor allele as compared to PBMC
that were homozygous for the major allele (1604C) (Unpaired T-
test; P=0.023) (figure 2). No differences in CypA expression were
observed in PBMC heterozygous for the 1650G minor allele
compared to PBMC homozygous for the 1650A major allele.
Next, we analyzed the replicative capacity of HIV-1 in PHA-
stimulated PBMC from healthy individuals with known genotypes
for the C1604G and A1650G polymorphism. PHA-stimulated
PBMC were inoculated with NL4-3 Ba-L (2610
3 TCID50 per
5610
6 cells). Subsequently, virus replication was assessed by
measuring p24 antigen levels in the culture supernatant every
other day for a period of two weeks. No significant differences in
p24 production were observed at any time point during the culture
period, irrespective of the genotype of the regulatory region of the
CypA gene (figure 3).
Discussion
CypA has been identified as a cofactor for HIV-1, leading to
enhanced infection by a largely unknown mechanism [2]. The
identification of Trim5-CypA fusion proteins as restriction factors
[16,17] and the dependency of Rhesus Trim5a on CypA has
renewed the interest in this ubiquitously expressed cellular protein
[11–14]. Here we analyzed the effects of polymorphisms in the
promoter region of the CypA gene on susceptibility for HIV-1
infection and disease progression in participants of the ACS.
In a previous study, 1604G was observed to be associated with a
more rapid CD4+ T-cell decline in African Americans and a trend
towards more rapid progression to AIDS was observed in
Figure 1. Survival analysis for C1604G and A1650G in DU of the ACS. Kaplan Meier analysis for time in months from seroconversion to viral
RNA load above 10
4.5 copies per ml plasma in DU of the ACS based on the C1604G genotype (left panel) or A1650G genotype (right panel). Black lines
indicate individuals homozygous for the major allele (left panel: 1604CC; right panel: 1650AA); Gray lines indicate individuals heterozygous for the
minor allele (left panel: 1604CG; right panel: 1650AG).
doi:10.1371/journal.pone.0003975.g001
Figure 2. Analysis of CypA expression levels. CypA mRNA levels
in PBMC obtained from healthy controls that were homozygous for the
1604 and 1650 major alleles (1604CC/1650AA), heterozygous for the
1604 minor allele (1604CG), or heterozygous for the 1650 minor allele
(1650AG). CypA mRNA levels were normalized for b-actin mRNA levels.
doi:10.1371/journal.pone.0003975.g002
Figure 3. Analysis of HIV-1 replication in genotyped PBMC.
Replication of NL4-3 Ba-L in PHA stimulated PBMC from healthy donors
homozygous for the 1604 and 1650 major allele (1604CC/1650AA),
heterozygous for the 1604 minor allele (1604CG), or heterozygous for
the 1650 minor allele (1650AG). Virus replication was analyzed by
measuring p24 production in culture supernatant. P24 production at
day 12 after infection is shown.
doi:10.1371/journal.pone.0003975.g003
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Caucasian MSM, no association between 1604G and progression
to AIDS or any other endpoint was observed. This is in agreement
with observations in the Swiss cohort of HIV-1 infected individuals
who are also all Caucasian [26].
In the ACS on HIV-1 infected drug users, we could also not
demonstrate an association between polymorphisms in the
regulatory region of the CypA gene and survival to CD4+ T-cell
counts below 200 cells per ml or AIDS according to the 1987 and
1993 definitions. In this cohort, however, time to plasma viral
RNA load above 10
4.5 copies per ml was significantly reduced in
1604G carriers. These observations suggest only a minor effect of
polymorphisms in the regulatory region of CypA which may
become apparent only during the late stages of infection when
viral load is increasing.
A second polymorphism in the regulatory region of the CypA
promoter involves position 1650. In a Swiss Caucasian cohort,
1650G was reported to be associated with a rapid CD4+ Tc e l ll o s s
and enhanced progression to disease [26]. An association between
the presence of 1650G and delayed disease progression was also
observed in a cohort of HIV-1 infected African Americans and a
trend towards a delayed progression to AIDS was observed in
European Americans [25]. We were unable to confirm these results
in our cohort of MSM. However, we did observe an enrichment of
the 1650G allele in MSM who have remained seronegative despite
high risk behavior (HRSN) as compared to HIV-1 infected MSM
which might indicate that the 1650G allele is associated with a
reduced susceptibility to HIV-1 infection. This contradicts findings
of an earlier study where a reduced prevalence of the 1650G allele
was observed in European Americans who remained seronegative
despite high risk behavior as compared to a seroconverter cohort
[25]. Furthermore, no effect of the 1650G allele on the HIV-1
susceptibility and replication was observed in an in vitro replication
assay using PHA stimulated PBMC from donors who were
homozygous for the 1650A allele or heterozygous for the 1650G
allele. However, in vitro infection of PHA stimulated PBMC may be
not reflective of in vivo transmission conditions.
The observed differences between our present study and earlier
reports [25,26] may be explained by differences in the study
populations. Interactions with other sequence variations that are
distributed differently between the populations, immunological
differences, different HIV-1 transmission routes, and differences in
the circulating virus populations may account for the variable
outcomes of these studies. Variations in natural history of HIV-1
infection among different HIV-1 infected cohorts have been reported
before. For example, heterozygosity for the 32 basepair deletion in
the CCR5 gene has a strong protective effect in the cohort of HIV-1
infected MSM of the ACS [18] whereas no effect on disease
progression was observed in HIV-1 infected DU of the ACS [29].
Polymorphisms in the promoter region of CypA may have an
effect on the CyPA expression levels and recently it was
demonstrated that the 1604G allele enhances binding of
transcription factors such as SP1, resulting in increased transcrip-
tion of the CypA gene [25,30]. Seemingly in contrast, we here
observed a reduction in CypA expression in PBMC isolated from
healthy C1604G heterozygous blood donors when compared to
PBMC from carriers of the major allele. However, another
polymorphism in the regulatory region of CypA, (C1575G), which
is in 100% linkage disequilibrium with the C1604G polymor-
phism, was shown to reduce nuclear factor binding and decrease
transcription of CypA [25]. Our results may thus indicate that the
effect of these polymorphisms on CypA transcription is dominated
by 1575G allele. However, the reduction in CypA expression
levels had no effect on HIV-1 replication in vitro using PHA
stimulated PBMC from donors who were homozygous or
heterozygous for the C1604G genotype.
Overall, we here show that polymorphisms in the regulatory
region of the CypA are only weakly associated with the clinical
course of infection in the ACS. However, considering the
important role of this protein in HIV-1 replication, manipulation
of CypA activity by therapeutic intervention should be seriously
considered.
Materials and Methods
Study participants
The study population, 364 Caucasian, MSM enrolled in the
Amsterdam Cohort studies (ACS) on the natural history of HIV-1
infection between October 1984 and March 1986, was previously
described [18]. The censor date of our study was set at the first day
of effective antiretroviral therapy of the participant or end of
follow-up. Of the 364 participants, 131 seroconverted during the
study. The remaining 233 men were positive for HIV-1 antibodies
at entry between October 1984 and April 1985. In previous
epidemiological studies, the time since seroconversion of these
prevalent cases has been estimated based on the incidence of HIV-
1 infection amongst MSM of the Amsterdam Cohort and was on
average 1.5 years before entry into the cohort studies [31]. For
analysis, we combined the 131 participants with documented
seroconversion and 233 seroprevalent participants with an
imputed seroconversion date as one study group, since previous
studies have not revealed differences in AIDS-free survival
between the two groups [21]. From 334 participants DNA
samples were available for analysis.
Sixty-eight MSM with high-risk behavior that persistently
remained HIV-seronegative (HRSN) were retrospectively selected
from the ACS. They remained seronegative during a follow up of
5 years before January 1996 and had reported unprotected
receptive anal intercourse with at least 2 different partners before
January 1996 (introduction of highly active antiretroviral therapy
(HAART)).
A second study population consists of 120 HIV-1 infected
intravenous drug users (DU) that participate in the Amsterdam
Cohort Studies on HIV and AIDS among intravenous drug users
which started enrolment in 1985. Asymptomatic men and women
who were living in the Amsterdam area and who reported
intravenous drug use in the preceding 6 months were enrolled in a
prospective study on the prevalence and incidence of HIV-1
infection and risk factors for AIDS. In our study, we included 84
individuals who seroconverted for HIV antibodies during active
follow-up. The median time between the last negative test and the
first positive test for this group of prospective seroconverters was
3.9 months (interquartile range, 3.7–5.1). At entry in the cohort
study 37 individuals were positive for HIV antibodies but had a
negative test result before entry (i.e., retrospective seroconverters).
Negative test results were obtained from samples taken for
hepatitis B virus serology. The median interval between the last
negative and first positive tests was 4.1 years (interquartile range,
1.8–5.4) for these seroconverters. For all 120 HIV infected DU (76
men and 44 women) used for our present analysis, the imputed
seroconversion date [31] was calculated and used for further
analysis.
Healthy volunteer blood donors (n=104) were used as HIV-1
negative control group. The ACS has been conducted in
accordance with the ethical principles set out in the declaration
of Helsinki and written informed consent is obtained prior to data
collection. The study was approved by the Academic Medical
Center institutional medical ethics committee.
CyPA Polymorphisms and HIV-1
PLoS ONE | www.plosone.org 4 December 2008 | Volume 3 | Issue 12 | e3975Genotyping for regulatory polymorphisms in CypA
DNA samples of 334 HIV+ MSM, 68 HRSN, 120 HIV+ DU
and 104 healthy controls were available for genotyping. For
analysis of the polymorphism in the promoter region of CypA,
DNA samples were amplified by PCR using Taq DNA polymerase
(Invitrogen) in the presence of 3 mM MgCl with primer pair
C1604G-F (59-GCACTGTCACTCTGGCGAAGTCGCAGAC-
39) and P4H-R (59-GCCGAGCACGTGCGTCGGACAGGAC-
39). The following amplification cycles were used: 5 min 95uC; 40
cycles of 30 s 95uC, 45 s 65uC, 60 s 72uC; 10 min 72uC.
Subsequently PCR products were subjected to a restriction digest
with 1U BstN1 (1 hour 60uC; New England Biolabs) to detect the
C1604G polymorphism or with 10U Rsa1 (1 hour 37uC; New
England Biolabs) to detect the A1650G polymorphism and
analyzed on a 1.25% agarose gel. A PCR product containing a
C at position 1604 or a G at position 1650 will result in a 524 bp
fragment (undigested) product. A PCR product containing a C at
position 1604 will result in digestion of the PCR product by BstN1
into a 423 bp and 101 bp fragments. A PCR product containing
an A at position 1650 will be digested with Rsa1 resulting in a
369 bp and 55 bp fragments.
CypA expression analysis and in vitro replication assay
Cells from 28 healthy blood donors were isolated, genotyped for
C1604G and A1650G and the CypA expression levels were
measured by real time Light cycler PCR. RNA was isolated by
Trizol (Invitrogen) according to the manufacturer’s protocol.
Subsequently, cDNA was prepared using the SuperScript
TM First-
Strand Synthesis System for RT-PCR (Invitrogen). CypA mRNA
levels were analyzed by SYBR green qPCR using the LightCycler
(Roche). The reaction mix contained 20 mM Tris-HCl (pH 8.4),
50 mM KCl, 3 mM MgCl2,2 0 0 mM dNTP, 250 mg/ml BSA,
500 nM primers, SYBR green I nucleic acid gel stain 40.0006
diluted in water, and 0.6 U platinum Taq DNA polymerase
(Invitrogen). The following primer sets were used for detection of
CypA cDNA: CypA-2F: 59-CTTCATCCTAAAGCATACGG-39
and CypA-2R: 59-CTTCTTGCTGGTCTTGCC-39.S e r i a l
dilutions of plasmid DNA containing cDNA of CypA were used
as a standard curve. To correct for differences in the cDNA
input, levels of b-actin cDNA were analyzed by a SYBR green
qPCR using the following primer set: BA-RNA-F 59-
GGCCCAGTCCTCTCCCAAGTCCAC-39 and BA-RNA-R 59-
GGTAAGCCCTGGCTGCCTCCACC-39. A serial dilution of
8E5 cells was used as a standard curve for b-actin. SYBR green
qPCR was performed using the following program on the
LightCycler: (1) preincubation and denaturation: 50uCf o r2m i n ,
95uC for 2 min; (2) amplification and quantification: 45 cycles of
95uC for 5 sec, 55uC for 15 sec, 72uC for 15 sec; (3) melting curve:
95uC for 0 sec, 65uC for 15 min, 95uC for 0 sec with a temperature
transition rate of 0.1uC/sec. Specificity of the PCR products
measured using the SYBR green method was confirmed by a
melting curve.
The replicative capacity of HIV-1 in PBMC from healthy blood
donors that were genotyped for C1604G and A1650G was
investigated. PBMC were isolated from buffy coats obtained from
healthy seronegative blood donors by Ficoll-isopaque density
gradient centrifugation. Cells (5610
6/ml) were stimulated for 2
days in Iscove’s modified Dulbecco medium (Whitaker) supple-
mented with 10% fetal calf serum (Hyclone), penicillin (Gibco Brl)
(100 U/ml), streptomycin (Gibco Brl) (100 mg/ml) and phytohe-
magglutinin (Welcome) (5 mg/ml). Cells were inoculated with
2000 TCID50 NL4-3(Ba-L) and replication was assessed by
measuring virus production in culture supernatants by in-house
p24 antigen capture enzyme-linked immunosorbent assay (ELISA)
[32].
Statistical analysis
Statistical analysis was performed employing SPSS (version 16).
The genetic effects of SNPs on HIV-1 susceptibility were assessed
by comparing the allelic and genotypic frequencies between
susceptibility groups using the Pearson chi square test. The minor
allele frequencies were compared to the most common genotype as
a reference group. Kaplan Meier and Cox proportional hazard
analysis were performed to study the genotypic association and
relative hazard (RH) between the C1604G and A1650G
polymorphisms in the regulatory regions of the CypA gene and
disease progression. The following endpoints were considered for
analysis: 1) AIDS according to the 1987 Centers for Disease
Control and Prevention (CDC) definition [27]; 2) AIDS according
to the 1993 CDC definition [28]; 3) CD4+ T cell counts below 200
cells/ml blood and 4. Viral RNA load above 10
4.5 copies per ml
plasma. CypA expression and differences in replicative capacity of
HIV-1 in genotyped donor PBMC were compared using the
student T-test. A result was considered significant if the P-value
was ,0.05.
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